Trial Profile

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mavrilimumab (Primary)
Indications COVID-19 pneumonia; Inflammation; Respiratory insufficiency
Focus Therapeutic Use

Most Recent Events

06 May 2021 Status changed from active, no longer recruiting to completed.
22 Dec 2020 According to a Kiniksa Pharmaceuticals media release, this study is also conducted at University of Cincinnati and Virginia Commonwealth University.
22 Dec 2020 According to a Kiniksa Pharmaceuticals media release, the company has closed the enrollment in this study early, as the company can focus on the registrational development program in the same patient population.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com